NAD+ side effects announce themselves most clearly in an infusion chair. Someone forty minutes into a drip asks the nurse to slow it down, because their chest feels tight, their face is flushed, they feel sick, and their calves have started to cramp. The rate comes down, the sensations ease, and the appointment continues for another two hours.
The vendor we point lifters to
NAD+ from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
Quoted per 100 mg because NAD+ is dosed in hundreds of milligrams, not the single milligrams a peptide vial holds. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Two independent lab reports per batch
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified August 20, 2026.
That reaction is the best documented adverse effect in this entire subject, and it is route specific. It tells you nothing about a capsule and nothing about a subcutaneous injection.
Sorting effects by route is therefore not fussiness. It is the only way the question has an answer, because the three products sharing this abbreviation have almost nothing in common at the level of evidence.
What the infusion reaction actually is
Intravenous NAD+ delivered quickly is reported to produce nausea, flushing, chest tightness, abdominal discomfort and cramping, and these reports are consistent enough that clinic practice is built around them. The standard response is to slow the infusion, which is why sessions run for hours rather than minutes.
The mechanism is not firmly established, and explanations offered include rapid metabolism of the infused compound and the downstream products it generates. Treating any of those explanations as settled would go beyond what has been shown.
What can be said is that the effect is rate related, immediate, and familiar to anyone who has sat through the procedure. It is also, notably, the only part of this subject where the human record is unambiguous.
NAD+ side effects sorted by route, because the routes differ
| Route | Reported effects | Quality of the record | Organism |
|---|---|---|---|
| Intravenous NAD+ | Nausea, flushing, chest tightness, cramping, rate related | Consistent reports, largely uncontrolled | Human |
| Oral nicotinamide riboside or nicotinamide mononucleotide | Generally tolerated in trial populations, mild gastrointestinal complaints reported | Trial reported, in the populations and durations studied | Human |
| Oral nicotinic acid | Flushing, well established for this precursor specifically | Long established | Human |
| Subcutaneous NAD+ from a research vial | Essentially unstudied in controlled form | No record to speak of | Human |
| Any route, effects on muscle tissue | No muscle specific toxicity reported | No outcome measured either way | None |
The fourth row is the one most readers of this page are actually using, and its record is blank.
What the oral precursor trials reported
The human safety information in this field comes almost entirely from oral precursors, which is worth stating every time, because it is repeatedly borrowed by products it does not describe.
Trials of oral nicotinamide riboside and of oral nicotinamide mononucleotide in humans have generally reported good tolerability at the amounts and durations studied, with mild and mostly gastrointestinal complaints. Nicotinic acid, a different precursor, is separately well known for causing flushing.
Two limits apply. Those trials ran for defined periods in defined populations, so they are not a statement about indefinite use by anyone. And tolerability is not efficacy. A compound can be entirely harmless and still do nothing, which is the more likely reading of the muscle level results in this literature.
The concerns that are raised but not demonstrated
Two theoretical concerns appear in the scientific discussion of NAD boosting, and both deserve to be reported as what they are.
The first is that increasing NAD availability could in principle support the metabolism of cells that are already proliferating abnormally. This is a mechanistic concern raised in the literature rather than a demonstrated harm in people, and it is discussed because the same pathways that support healthy tissue support unhealthy tissue.
The second involves methyl donor consumption, since clearing excess nicotinamide uses methyl groups. Again, a hypothesis discussed in the field rather than an established clinical problem.
Neither should be presented as a known risk. Neither should be omitted either, because a page that lists only the mild gastrointestinal complaints is describing the comfortable part of the record.
Risks that come from the vial rather than the molecule
For anyone using an injected product bought as research material, the compound may not be the main hazard.
There is no approved injected NAD+ medicine in any market. That means no pharmacopoeial standard, no batch release testing anyone is accountable for, and no regulator who can act on a bad lot. Identity, purity, concentration and sterility are asserted by the seller.
A vendor certificate of analysis describes a sample at a point in time. It is not a statement about the vial in front of you, and it typically says nothing about sterility of the finished product or about what happened in transit and storage.
Injection of a non sterile preparation carries infection risk that exists independently of whatever the molecule does or does not do. That risk is concrete, unlike most of the benefits attached to the same product.
Where this collides with a training block
Nothing here suggests a direct effect on muscle tissue, in either direction, and no muscle specific toxicity has been reported.
The practical intersections are more mundane. An infusion appointment that produces hours of nausea and cramping is a lost training day, and possibly two. A subcutaneous injection site reaction is a nuisance at best. And an unverified injected product carries an infection risk that would cost far more training time than any plausible benefit would return.
There is also a subtler cost. Someone attributing a good training phase to a compound that has never demonstrated a muscle effect is misattributing their own work, which matters when they later decide what to keep doing and what to drop.
What long term use has not established
Duration is the gap that swallows most of this. Human trials of oral precursors ran for defined periods, and the injected form has essentially no controlled record at any duration.
So questions about years of use, about accumulating effects, about interactions with medications, and about use in people with existing conditions do not have answers derived from evidence. They have answers derived from the absence of reports, which is a different and much weaker thing, particularly for a product no surveillance system is watching.
The pieces a real safety profile needs, and which are absent
It is worth being explicit about what a safety profile consists of, because the phrase gets used loosely and the gap here is structural rather than a matter of a few missing studies.
A profile needs a defined product, so that what was tested is what is sold. Injected NAD+ has no approved formulation, so the tested object and the purchased object are not the same in any verifiable way.
It needs a dose range, so that effects can be attached to amounts rather than to habits. No dose ranging work exists for the injected form.
It needs comparison groups, because without a placebo arm every unpleasant sensation and every pleasant one is uninterpretable. It needs defined populations with exclusions, so that people at particular risk are identified rather than discovered. It needs duration, because effects that emerge after a year are invisible in a trial that ran for weeks. And it needs post market surveillance, a system that counts what goes wrong once real numbers of people are exposed.
Oral precursors have some of these, within the limits of supplement regulation. Injected NAD+ has essentially none of them. That is why the honest answer to most safety questions about the injected form is not reassuring or alarming but simply unknown, and unknown in a way no amount of anecdote will resolve.
Questions people ask about tolerability
Are NAD+ side effects well documented?
For intravenous infusion, the immediate rate related reaction is consistently reported. For oral precursors, trial tolerability data exist. For the injected research vial, there is effectively no record.
Does the infusion reaction mean it is working?
No. It is a reaction to how quickly the compound is delivered, and clinics reduce it by slowing the rate. Nothing connects its intensity to any outcome.
Do the oral safety data cover an injection?
No. They describe a different molecule taken by a different route, and the safety profile of one route cannot be assumed for another.
Is it safe for long term use?
Unknown for both forms. The human trials of precursors ran for defined periods, and the injected form has no controlled long term record at all.
Could it interact with medication I take?
Interaction data for injected NAD+ are absent, and anyone taking prescribed medication should raise it with the prescriber rather than rely on the absence of published reports.
Does the absence of reported problems mean there are none?
No. For an unapproved injected product there is no reporting system collecting problems, so silence reflects the absence of counting rather than the absence of events.